Medicus advances Teverelix development with EU Phase 2b trial submission in Prostate Cancer

Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to discuss the company’s successful submission of a substantial modification application through the European Union Clinical Trials Information System (CTIS), supporting the planned Phase 2b study of Teverelix® in advanced prostate cancer. Mehmud said the submission marks an important step in advancing Teverelix® toward registrational development, with a particular focus on prostate cancer patients who have elevated cardiovascular risk and require androgen deprivation therapy (ADT). This patient population represents a significant unmet medical need, as cardiovascular complications remain a major consideration in treatment selection and long-term management. The planned Phase 2b study is designed to optimize dose selection and further evaluate the pharmacokinetic, pharmacodynamic, efficacy, and safety profile of Teverelix® ahead of later-stage development. The data generated will help guide ...